Richard Morgan
MANAGING PARTNER
Richard Morgan has played an active role in the development of over 40 life science and technology companies, including MediSense, Quidel, Celgene (all listed on NASDAQ) and, most recently, Kromek Group, MotifBio, and Polarean Imaging, each of which was listed on the London Stock Exchange. He is currently a non-executive board member of ILC Therapeutics Ltd, a private biotech company based in Scotland, UK.
Richard co-founded Celgene in 1987, serving as Chairman and CEO before recruiting a new CEO. He remained on the board for 20 years, serving on the Executive Committee and chairing the Compensation Committee until his retirement in 2008. He was Founder and Chief Executive Officer of Amphion Innovations plc. Prior to founding Amphion, Richard was a Managing Partner at Wolfensohn Partners LP which followed 15 years at Schroders plc, then a leading British merchant bank.
At Schroders Richard started as a financial analyst and later became a member of the main board of the merchant bank, initially in the investment division and then as head of the Schroder Strategy Group, which he founded. Under his leadership the Schroder Strategy Group gave strategic and financial advice to over one hundred corporations around the world.
Richard, a British citizen, was raised in Kenya and educated in England. He lived in New Zealand for a number of years and graduated with a Bachelor of Engineering, with First Class Honors, from the University of Auckland, New Zealand, where he also did postgraduate research into materials science and aerospace structures, under an Open Scholarship. In 1982 he completed the Advanced Management Program at the Harvard Business School.
Peter Bains
MANAGING PARTNER
Peter currently serves as a Non-Executive Director for MiNA Therapeutics, Apterna, and Indivior, a FTSE listed company. He is also Chairman of ILC Therapeutics, a private company.
Peter has over three decades of experience in the biotech and pharmaceutical industry, which included a 23-year career at GlaxoSmithKline, in which he was, among his other roles, Head of Global Marketing and Senior VP of Commercial Development for GSK’s International Region. During the period, he helped establish several GSK brands as brand leaders and conceived, developed and implemented an organizational redesign in GSK’s International Region. Peter led the pharmaceuticals and vaccines operational strategy, planning and execution in Latin America, Middle East, South-East Asia and Australasia, China, and Canada. He was also a Member of various GSK teams with strategic, operations, marketing, and business development responsibilities and a Member of the Board of Directors of GSK India. He also served as the Representative Executive Officer and Chief Executive Officer of Sosei Group Corporation, a Tokyo listed biotech company, and Chief Executive Officer of Syngene International, which he successfully took public on the Mumbai Exchanges in 2015.
From 2009, he has been a consultant specializing in supporting strategic growth opportunities in small- and medium-sized innovation-based life science companies.
Peter has a BSc Combined (Honours) in Physiology/Zoology from Sheffield University.
RAYMOND MCKENZIE
ADVISOR
Raymond is a private investor who specializes in co-investing with proven venture capital enhanced value creators. Raymond was a member of the Board of Directors of a number of Partner Companies of Amphion Innovations: FireStar Software Inc. from 2005-2013, Energy Trading International (PrivateMarkets Inc.) from 2005-2013, and m2m Imaging Inc. (the predecessor to Polarean Imaging Inc.) from 2008-2013.
Prior to this, Raymond spent 16 years at New York based investment bank, Lazard Frères & Co. Inc., specializing in Capital Markets (1985-1998) where he was Vice President. Previous to that, he was an analyst/ programmer at Morgan Stanley & Co., Inc. from 1983-1985.
Raymond received a Bachelors degree in Physics from Dartmouth College, New Hampshire in 1983. He is a dual national of Barbados and Great Britain.
RAY TABIBIAZAR, MD
ADVISOR
Dr. Tabibiazar is a seasoned executive with leadership experience in healthcare and biopharma industry that included venture capital, pharmaceutical, diagnostics, and life sciences. He is currently the managing director of 526 Ventures LLC, a life sciences strategic consulting company working with several public and private biopharmaceutical firms. Previously, he has held a number of board and executive positions in several biotech companies including Saliogen Therapeutics and Aravive Biologics. In addition, he served as SVP of Corporate Development and Business Strategy at Twist Biosciences (Nasdaq: TWST), SVP of Corporate Development at Synthetic Biologics (Nasdaq: SYN), Chief Scientific Officer of Aviir, and Vice President of Translational Research for VIA Pharmaceuticals (Nasdaq: VIAP, reincarnated as MDGL). Ray was also a venture partner at Bay City Capital LLC a large VC firm with focus on new venture formation. Before moving to industry, Dr. Tabibiazar was a practicing cardiologist and an adjunct clinical instructor in medicine at Stanford University. Dr. Tabibiazar received his medical degree from Harvard Medical School and trained as an internist and cardiologist at Stanford University, while also receiving finance education at Stanford Business School. Dr. Tabibiazar received board certifications in Internal Medicine, Cardiovascular Medicine, Nuclear Medicine, and Cardiovascular Imaging.
CHARLIE MORGAN
DESIGN & COMMUNICATIONS
Charlie is responsible for the design and communications for Twiga Group. Previously, she served as the Corporate Communications Coordinator at Amphion Innovations US Inc., an AIM listed company, preserving open channels amongst executives, Board Members, shareholders, and vendors (both domestically and abroad). She directly supported the IPOs of a number of companies [Amphion Innovations plc (AIM:AMP), Kromek Group plc (AIM:KMK), Motif Bio plc (AIM & NASDAQ: no longer listed), and Polarean Imaging plc (AIM:POLX)], providing communications support both pre and post listing, ensuring all regulatory requirements were met.
In addition to her work in corporate communications, Charlie is a graphic designer. She has a number of design clients ranging from startup companies to an Emmy nominated television show and University College, Oxford. She brings branding and corporate identity development expertise to Twiga Group where she created, implemented, and executed the Group’s branding.
A dual citizen, Charlie was born in the UK but raised and educated in the USA, Charlie has an AAS degree from Parsons School of Design where she graduated with honors, and a BA from Lafayette College where she studied Art History and English. She also speaks Italian. Visit her design website here.